RMC-6291 is under clinical development by Revolution Medicines and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RMC-6291’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RMC-6291 is under development for the treatment of solid tumor, non-small cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma. The drug candidate is a second-generation, tri-complex inhibitors. It is administered through oral route. It acts by targeting the GTP bound form of KRAS (G12C) and NRAS (G12C).
Revolution Medicines overview
Revolution Medicines operates as a drug development company that discovers and develops new medicines and therapies for cancer patients. The company develops SHP2 Program, 4EBP1 Program and mTORC1 Program. It provides the REVBLOCKS platform, an integrated suite of modular synthesis methodologies which facilitates the production of a pipeline of drug candidates with properties based on the complex structures found in natural products. Revolution Medicines exposes advantageous structural and functional properties of scaffolds and ligands. The company also develops small molecule inhibitors of protein tyrosine phosphates and bRo5 small molecule drug candidates. It partners with pharmaceutical companies and healthcare organizations for its drug development activities. Revolution Medicines is headquartered in Redwood City, California, the US.
For a complete picture of RMC-6291’s drug-specific PTSR and LoA scores, buy the report here.